Skip to content

observational feedback clinical trial on anti-dandruff shampoo

An observational, consumer feedback and claim substantiation study of an anti-dandruff shampoo

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042609
Enrollment
50
Registered
2022-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L218- Other seborrheic dermatitis

Interventions

Intervention1: Solimo Natural Anti-dandruff shampoo (500ml): Dosage : liquid Usage: Daily basis Duration: 30 days Control Intervention1: NIL: NIL

Sponsors

Amazon Development Centre India Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Indian male and female volunteer aged between 18-60 years (both inclusive) ii. Willing to give Informed Consent iii. Subjects with the complaints of dandruff in hair iv. Willing to complete the study assessments/questionnaires. v. Willing to avoid usage of his/her own shampoo, hair oils and other hair products for at least one week before Commencement and during this study

Exclusion criteria

Exclusion criteria: i. Pregnancy or breast feeding. ii. Patients with pre existing severe systemic disease necessitating long term medication. iii. Evidence of significant uncontrolled co morbid disease which in the investigators opinion would jeopardize patient participation. iv. History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ v. Any neurological (congenital or acquired), vascular or systemic disorder which could affect any of the efficacy assessments. vi. Participation in the current or previous treatment with any approved or investigational health supplement s during the past 1 month

Design outcomes

Primary

MeasureTime frame
1.To evaluate Consumer acceptance as well as their reaction to the product. 2.To test customerâ??s utility pattern of the product. Timepoint: Day 0 to Day 30

Secondary

MeasureTime frame
To monitor concomitant medication and Adverse eventsTimepoint: Day 0 to Day 30

Countries

India

Contacts

Public ContactDr Ashok Godavarthi

Radiant Research Services Pvt. Ltd

ashok@radiantresearch.in9880999297

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026